Publications by authors named "Maria A Sullivan"

Claim this Profile
S
Self-Reported Cognitive Impairments in Office-Based Treatment for Opioid Use Disorder with Buprenorphine or Extended-Release Naltrexone.
Efrat Aharonovich, Dvora Shmulewitz, Abigail Zavod, Elizabeth Keane, Anna Legedza, Maria A Sullivan

Subst Use· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trials.
Matisyahu Shulman, Mei-Chen Hu, Maria A Sullivan, Miranda Greiner, Kaitlyn Ohrtman

Am J Addict· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate-to-severe alcohol use disorder.
Regina Grebla, Teresa L Kauf, Angela Lax, Erin E Cook, Yilu Lin, Amy K O'Sullivan, Maria A Sullivan

Am J Addict· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Journey and Healthcare Resource Use Among Patients With Alcohol Use Disorder Who Initiated Extended-Release Naltrexone: An Analysis of Veterans Affairs Data.
Regina Grebla, Jieruo Liu, Amy K O'Sullivan, Sherry Shi, Elyse Swallow, Maria A Sullivan

Subst Use· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder.
Brittany D Roy, Jianheng Li, Cathy Lally, Sarah C Akerman, Maria A Sullivan

BMC Psychiatry· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Matisyahu Shulman, Mei-Chen Hu, Maria A Sullivan, Sarah C Akerman, James Fratantonio

Drug Alcohol Depend· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Paolo Mannelli, Antoine B Douaihy, Sarah C Akerman, Anna Legedza, James Fratantonio, Maria A Sullivan

Am J Addict· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Paolo Mannelli, Antoine B Douaihy, Abigail Zavod, Anna Legedza, Sarah C Akerman, Maria A Sullivan

Am J Drug Alcohol Abuse· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.
Priya Jain, Kimberley McKinnell, Rose Marino, Prashanthi Vunnava, Marie A Liles-Burden, Maria A Sullivan

Drug Saf· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Thomas Kosten, Efrat Aharonovich, Narinder Nangia, Abigail Zavod, Sarah C Akerman, Maria A Sullivan

Addict Behav· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Edward V Nunes, Adam Bisaga, Evgeny Krupitsky, Narinder Nangia, Bernard L Silverman, Maria A Sullivan

Addiction· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder.
Abigail Zavod, Sarah C Akerman, Martha M Snow, Matt Tierney, Maria A Sullivan

J Am Psychiatr Nurses Assoc· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Sandra D Comer, Paolo Mannelli, Danesh Alam, Antoine Douaihy, Narinder Nangia, Maria A Sullivan

Am J Addict· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Edward V Nunes, Adam Bisaga, Evgeny Krupitsky, Narinder Nangia, Bernard L Silverman, Maria A Sullivan

Addiction· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.
Maria A Sullivan, Adam Bisaga, Martina Pavlicova, Kenneth M Carpenter, C Jean Choi

Am J Psychiatry· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Andrew J Saxon, Sarah C Akerman, Chih-Chin Liu, Maria A Sullivan, Bernard L Silverman

Addiction· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Adam Bisaga, Paolo Mannelli, Miao Yu, Narinder Nangia, Christine E Graham, Maria A Sullivan

Drug Alcohol Depend· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.
Adam Bisaga, Paolo Mannelli, Maria A Sullivan, Suzanne K Vosburg, Peggy Compton

Am J Addict· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder.
Verena E Metz, Maria A Sullivan, Jermaine D Jones, Elizabeth Evans, Rachel Luba

J Psychoactive Drugs· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.
Verena E Metz, Jermaine D Jones, Jeanne Manubay, Maria A Sullivan, Shanthi Mogali

Neuropsychopharmacology· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.
Frances R Levin, Adam Bisaga, Maria A Sullivan, Arthur Robin Williams, Kathryn Cates-Wessel

Am J Addict· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.
Ziva D Cooper, Kirk W Johnson, Martina Pavlicova, Andrew Glass, Suzanne K Vosburg, Maria A Sullivan

Addict Biol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.
Jermaine D Jones, Maria A Sullivan, Jeanne M Manubay, Shanthi Mogali, Verena E Metz

Physiol Behav· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Frances R Levin, John J Mariani, Martina Pavlicova, Daniel Brooks, Andrew Glass, Maria A Sullivan

Drug Alcohol Depend· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Adam Bisaga, Maria A Sullivan, Andrew Glass, Kaitlyn Mishlen, Martina Pavlicova

Drug Alcohol Depend· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis